Power Law company profile

Everest Medicines

Biotech & Life Sciences · New York City, United States · Founded 2017 · IPO 2020 Unicorn

Developing and commercialising novel transformative pharmaceutical therapies

Valuation

$1.22B

Market cap · May/2026

Revenue

$235M

Latest reported FY

EBITDA

$40M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

6 investors on Everest Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

HBM Healthcare Investments

Cormorant Asset Management

CBC Group

Series B+ 3 investors entered at this stage

RA Capital Management

Hillhouse Capital

Janchor Partners

Global footprint

Where Everest Medicines has talent and traffic

Workforce by country

7 countries with
team presence

🇨🇳 China86.1%

🇺🇸 United States6.4%

🇹🇼 Taiwan2%

🇸🇬 Singapore2%

🇭🇰 Hong Kong1.6%

Top 5 of 7 shown

Web traffic by country

56K monthly visits
across markets

🇨🇳 China94.1%

🇺🇸 United States3.4%

🇮🇳 India1.1%

🇭🇰 Hong Kong0.9%

Top 4 markets shown

Market sentiment

What the market is saying about Everest Medicines

An AI-synthesized read of the highest-engagement posts about Everest Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Everest Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles